Myeloperoxidase, Subclinical Atherosclerosis, and Cardiovascular Disease Events

Division of Cardiology, University of California, Irvine, California, USA.
JACC. Cardiovascular imaging (Impact Factor: 6.99). 09/2009; 2(9):1093-9. DOI: 10.1016/j.jcmg.2009.05.012
Source: PubMed

ABSTRACT We evaluated whether myeloperoxidase (MPO) predicts future cardiovascular disease (CVD) events in asymptomatic adults and whether subclinical atherosclerosis may affect this relation.
Myeloperoxidase is a leukocyte-derived enzyme-generating reactive oxidant species that has been shown to predict risk of CVD in selected populations.
We studied 1,302 asymptomatic adults (mean age 59 years, 47% women) without known CVD who were followed for 3.8 years. We measured MPO by the use of immunoassay. Coronary artery calcium (CAC), a measure of subclinical atherosclerosis, was measured by computed tomography with the Agatston score categorized as none/minimal (0 to 9), mild (10 to 99), and moderate/significant (> or = 100). Cox regression, adjusted for age, sex, and other risk factors, examined the relation of CAC and/or MPO with incident CVD events.
Persons with MPO levels at or above compared with below the median (257 pM) were more likely (p < 0.05 to p < 0.001) to be women, have a higher body mass index, greater low-density lipoprotein cholesterol, greater systolic and diastolic blood pressure, and lower high-density lipoprotein cholesterol. Mean MPO levels increased according to CAC categories (p trend = 0.02). Incident CVD events were more likely in those at or above versus below the median MPO level (4.6% vs. 2.3%, p = 0.02), even after adjustment for age, sex, CAC, and risk factors (hazard ratio [HR]: 1.9, 95% confidence interval: 1.0 to 3.6, p = 0.04). Combining CAC and MPO categories, CVD incidence ranged from 0.6% in those with a CAC score of 0 to 9 to 7.1% (adjusted HR: 9.2, p < 0.001) in those with CAC scores of > or = 100 and MPO below the median and 14.0% (adjusted HR: 19.5, p < 0.0001) in those with CAC scores of > or = 100 and MPO at or above the median.
Our study suggests persons with both increased levels of both MPO and CAC are at an increased risk of CVD events. Imaging of subclinical atherosclerosis combined with assessment of biomarkers of plaque vulnerability may help improve CVD risk stratification.

Download full-text


Available from: Heidi Gransar, Jan 15, 2015
  • Source
    • "Another study included 1,302 asymptomatic adults (mean age 59 years, 47% women) without known CVD who were followed for 3.8 years. After measuring MPO and coronary artery calcium, by computed tomography, the study suggested that persons with both increased levels of both MPO and CAC are at an increased risk of CVD events [189]. However, the concentration of MPO depends on the assay method, sampling material, and preanalytical and analytical procedures. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Atherosclerotic cardiovascular disease is the leading cause of death in many developed countries. It is characterized by complex endocrine, paracrine and juxtacrine interactions between immune and vascular cells, as well as several tissues and organs. Oxidative stress and inflammation have an important role in the promotion of atherosclerotic cardiovascular disease. Considering the complicated mechanisms and signals involved in atherosclerosis, research is focused on blood-based biomarkers, gene-based markers, metabolomics and other potentially interesting approaches for biomarker discovery. These biomarkers can be introduced as routine diagnostic tests if they prove to be cost-effective and to predict future cardiovascular events. Given the overlap of circulating inflammatory and oxidative stress biomarkers in atherosclerosis and rheumatic diseases, we aim to overview their potential to screen cardiovascular risk and also to predict the evolution of associated rheumatic diseases.
    Current pharmaceutical design 04/2013; · 3.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Inflammation and oxidative stress play central roles in the pathogenesis of atherosclerosis and outcomes such as myocardial infarction and stroke. The enzyme myeloperoxidase (MPO) is secreted by activated leukocytes in atherosclerotic plaques and generates several pro-oxidative species that participate in biological activities that promote plaque destabilization and rupture; the catastrophic event that defines which plaques are benign and which are life-threatening. Serum MPO levels are also highly predictive of downstream cardiovascular events and patient outcome. Recently, several molecular imaging probes sensitive to the presence of MPO activity have been developed. Here we review the design and application of probes developed for MRI, single photon emission CT, and fluorescence and bioluminescence imaging. Continued development of these probes may one day allow detection of plaques prior to plaque rupture, yielding significant diagnostic and prognostic improvements and ultimately allowing proper staging and treatment of high-risk patients. KeywordsMyeloperoxidase–Atherosclerosis–Vulnerable plaque–Monocyte/macrophage–Neutrophil–Oxidative stress–Hydrogen peroxide–Hypochlorous acid–Myocardial infarction–Stroke–Molecular imaging–Magnetic resonance imaging–Single photon emission computed tomography–Bioluminescence imaging–Fluorescence imaging
    Current Cardiovascular Imaging Reports 01/2011; 4(1):24-31. DOI:10.1007/s12410-010-9056-2
  • [Show abstract] [Hide abstract]
    ABSTRACT: Myeloperoxidase (MPO), a member of the peroxidase family, emerged as a major player in the initiation and propagation of atherosclerotic cardiovascular disease (CVD). Evidence for its role in atherosclerosis include that MPO: a) induces endothelial dysfunction, b) modifies physiologically functional high density lipoprotein (HDL) into “dysfunctional HDL”, c) converts low density lipoprotein (LDL) into more atherogenic modified LDL form, and d) induces endothelial cell death and tissue factor expression involved in plaque vulnerability. Elevated levels of blood MPO are associated with CVD, predict incident risks for myocardial infarction and cardiac death in subjects with acute coronary syndrome, and predict future risk of coronary artery disease (CAD) in healthy individuals. In this article, we review current understandings on the role of MPO in pathophysiological processes involved in atherosclerosis and CVD.
    Current Cardiovascular Risk Reports 04/2013; 7(2). DOI:10.1007/s12170-013-0291-3
Show more